The risk for severe RSV-related outcomes was effectively reduced among children and infants who received nirsevimab in real-world clinical settings.

Adults as young as 50 may now qualify for an RSV vaccine if they have certain health conditions, according to a recent CDC update.

Seek Labs, a biotech company boldly seeking a healthier world through AI-powered discovery, programmable therapeutics, and point-of-care diagnostics, today announced successful mapping of the ...

In a new consensus statement, the European Society of Cardiology has declared vaccinations for common infections to be a ...

Respiratory syncytial virus is common but it can be dangerous for some infants and young kids. Here's everything parents need ...

Doctors Answer Your Questions About RSV While a potential COVID winter surge and the impending flu season get a lot of attention, doctors are worried about another virus. This one is RSV -- short for ...

The Trump administration appears to be expanding RSV vaccinations to some adults starting at age 50 instead of 60 ...

The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...

A newly configured federal vaccine panel's June 25 action is expected to improve options to protect infants from potentially deadly RSV.

The CDC's Advisory Committee on Immunization Practices (ACIP) has issued new vaccine recommendations affecting RSV and flu immunizations in 2025. The panel voted to expand RSV protection for infants ...